Cargando…

Higher Adherence to Treatment With Low-Molecular-Weight-Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-Associated Venous Thromboembolism

Current guidelines recommend low-molecular-weight-heparins (LMWH) monotherapy for 3 to 6 months as first-line treatment for cancer-associated venous thromboembolism (VTE). In clinical practice, enoxaparin and nadroparin are common agents used. However, differences in therapy adherence between these...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Wall, Sake J., Klok, Frederikus A., den Exter, Paul L., Barrios, Deisy, Morillo, Raquel, Cannegieter, Suzanne C., Jimenez, David, Huisman, Menno V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745948/ https://www.ncbi.nlm.nih.gov/pubmed/31723748 http://dx.doi.org/10.1097/HS9.0000000000000019

Ejemplares similares

Nadroparine calcium or enoxaparine in acute coronary syndrome patients suffering renal insufficiency: The nadroparin versus enoxaparin (NaVe) study design
por: Gurfinkel, Enrique P, et al.
Publicado: (2004)

Low-molecular-weight heparins in the treatment of venous thromboembolism
por: Ageno , Walter, et al.
Publicado: (2000)

Effectiveness and Safety of Nadroparin Therapy in Preterm and Term Neonates with Venous Thromboembolism
por: Sol, Jeanine, et al.
Publicado: (2021)

Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice
por: Hendriks, Stephan V., et al.
Publicado: (2020)

Comment on 'D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis'
por: Klok, Frederikus A., et al.
Publicado: (2019)

Fondaparınux Versus Nadroparın for Preventıon of Venous Thromboembolısm After Electıve Hıp and Knee Arthroplasty()
por: Argun, Mahmut, et al.
Publicado: (2013)

COVID‐19 associated coagulopathy and thromboembolic disease: Commentary on an interim expert guidance
por: Cannegieter, Suzanne C., et al.
Publicado: (2020)

Estimating incidence of venous thromboembolism in COVID‐19: Methodological considerations
por: Nab, Linda, et al.
Publicado: (2022)

Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism
por: Kooiman, Judith, et al.
Publicado: (2015)

The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients
por: Pineo, Graham F, et al.
Publicado: (2012)

Prevention of venous thromboembolism with enoxaparin in bariatirc surgery
por: Woo, Hee Doo, et al.
Publicado: (2013)

The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment
por: Kooiman, Judith, et al.
Publicado: (2015)

Safety of Enoxaparin as Venous Thromboembolism Prophylaxis After Rhytidectomy
por: Lisiecki, Jeffrey L., et al.
Publicado: (2019)

Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis
por: Delluc, Aurélien, et al.
Publicado: (2020)

Rare complication of nadroparin injections: Skin necrosis and heparin‐induced thrombocytopenia syndrome
por: Malinauskiene, Laura, et al.
Publicado: (2022)

Optimal Dosing of Enoxaparin in Critically Ill Patients with Venous Thromboembolism
por: Abdulla, Aliya, et al.
Publicado: (2023)

Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review
por: van der Wall, Sake J., et al.
Publicado: (2018)

Tumor‐expressed microRNAs associated with venous thromboembolism in colorectal cancer
por: Anijs, Rayna J. S., et al.
Publicado: (2022)

Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in Low Body Weight Patients
por: Dybdahl, Daniel, et al.
Publicado: (2019)

Pharmacological properties of betrixaban
por: Huisman, Menno V, et al.
Publicado: (2018)

First do no harm
por: Huisman, Menno V., et al.
Publicado: (2022)

Enoxaparin-sodium/heparin: Heparin-induced thrombocytopenia: case report
Publicado: (2021)

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study
por: Trujillo‐Santos, Javier, et al.
Publicado: (2022)

Enoxaparin sodium/heparin: Heparin-induced thrombocytopenia: 2 case reports
Publicado: (2021)

Efficacy and Safety of Enoxaparin for Preventing Venous Thromboembolic Events following Urologic Laparoscopic Surgery
por: Nomura, Takeo, et al.
Publicado: (2013)

Bemiparin versus Enoxaparin in the Prevention of Venous Thromboembolism among Intensive Care Unit Patients
por: Abbas, Mohamed Sayed
Publicado: (2017)

The use of enoxaparin as venous thromboembolism prophylaxis in bariatric surgery: A retrospective cohort study
por: Altawil, Esraa, et al.
Publicado: (2022)

742 Evaluation of Anti-Xa Levels and Venous Thromboembolism Prophylaxis with Enoxaparin in Burn Patients
por: Boyd, Allison, et al.
Publicado: (2023)

A systematic review of biomarkers among hospitalized patients with COVID‐19 predictive of venous thromboembolism: A communication from the Predictive and Diagnostic Variables Scientific and Standardization Committee of the ISTH
por: Woller, Scott C., et al.
Publicado: (2022)

The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model
por: Debergh, I, et al.
Publicado: (2010)

Prophylaxis and treatment of COVID-19 related venous thromboembolism
por: Kaptein, F.H.J., et al.
Publicado: (2021)

Safety of heparin prophylaxis for venous thromboembolism in patients with neurotrauma
por: Puri, G, et al.
Publicado: (2010)

Diagnostic Management of Acute Pulmonary Embolism in COVID-19 and Other Special Patient Populations
por: Martens, Emily S. L., et al.
Publicado: (2022)

“ISTH guidelines for antithrombotic treatment in COVID‐19”: Comment from Huisman et al.
por: Huisman, Menno V., et al.
Publicado: (2022)

Sensitivity of a Simple Noninvasive Screening Algorithm for Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary Embolism
por: Ende-Verhaar, Yvonne M., et al.
Publicado: (2018)

Comparison of Low-Molecular-Weight Heparins Prepared From Ovine Heparins With Enoxaparin
por: Chen, Jianle, et al.
Publicado: (2019)

Enoxaparin-sodium/heparin: Heparin-induced thrombocytopenia and lack of efficacy: case report
Publicado: (2020)

Enoxaparin sodium: Heparin-induced thrombocytopenia: case report
Publicado: (2021)

Enoxaparin-sodium/heparin: Lack-of-efficacy: case report
Publicado: (2022)

Enoxaparin sodium: Heparin-induced thrombocytopenia: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_23u1hhsnpgvl5vktd98g7813o0